| Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230] | Technology appraisal guidance | TBC |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368] | Technology appraisal guidance | |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110 | Technology appraisal guidance | TBC |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256 | Technology appraisal guidance | TBC |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
| Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway | Health technology evaluation | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| Breast cancer guidelines | NICE guideline | TBC |
| Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114] | Technology appraisal guidance | TBC |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |
| Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] | Technology appraisal guidance | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
| COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment | Health technology evaluation | TBC |
| Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289] | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220] | Technology appraisal guidance | TBC |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
| Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906] | Technology appraisal guidance | TBC |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | TBC |
| Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update) | NICE guideline | |
| Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177 | Technology appraisal guidance | TBC |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333] | Technology appraisal guidance | |
| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 | Technology appraisal guidance | TBC |
| Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
| Kidney Cancer | NICE guideline | TBC |
| Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966] | Technology appraisal guidance | TBC |
| LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update) | NICE guideline | TBC |
| Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
| Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] | Technology appraisal guidance | TBC |
| Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance | TBC |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102] | Technology appraisal guidance | TBC |
| Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248] | Technology appraisal guidance | TBC |
| Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205] | Technology appraisal guidance | TBC |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336] | Technology appraisal guidance | |
| Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065] | Technology appraisal guidance | TBC |
| Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] | Technology appraisal guidance | TBC |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120] | Technology appraisal guidance | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Technology appraisal guidance | TBC |
| Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094] | Technology appraisal guidance | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907] | Technology appraisal guidance | |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207 | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] | Technology appraisal guidance | TBC |
| Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332 | Technology appraisal guidance | TBC |
| Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103] | Technology appraisal guidance | TBC |
| Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873] | Technology appraisal guidance | TBC |
| Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985] | Technology appraisal guidance | TBC |
| Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381 | Technology appraisal guidance | TBC |
| Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742] | Technology appraisal guidance | TBC |
| Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361] | Technology appraisal guidance | TBC |
| Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
| Pralsetinib for thyroid cancer [ID4018] | Technology appraisal guidance | TBC |
| Relugolix for treating hormone-sensitive prostate cancer [ID6187] | Technology appraisal guidance | TBC |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100] | Technology appraisal guidance | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069] | Technology appraisal guidance | |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
| Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132] | Technology appraisal guidance | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293] | Technology appraisal guidance | |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | |
| SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Technology appraisal guidance | TBC |
| Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] | Technology appraisal guidance | |
| Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
| Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] | Technology appraisal guidance | TBC |
| Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070] | Technology appraisal guidance | TBC |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161] | Technology appraisal guidance | TBC |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162] | Technology appraisal guidance | TBC |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
| Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | TBC |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298] | Technology appraisal guidance | |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | |
| Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061] | Technology appraisal guidance | TBC |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |